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ABSTRACT
Introduction: Sodium glucose co-transporter 2
(SGLT2) inhibitors, such as dapagliflozin, have
demonstrated favorable effects in patients with
type 2 diabetes (T2D). However, there are lim-
ited reports in the literature regarding the glu-
cose-lowering effects of SGLT2 inhibitors in
actual clinical settings.
Methods: The post-marketing surveillance data
from a longitudinal prospective study of 2007
patients with T2D who were prescribed dapa-
gliflozin (10 mg/day) were analyzed (Clini-
calTrials.gov, NCT02252224).
Results: After 12 weeks of dapagliflozin treat-
ment, glycated hemoglobin (HbA1c) and body
mass index were significantly decreased
(P\0.001) from 8.1 ± 1.3% to 7.5 ± 1.2% and
from 28.1 ± 4.4 to 27.6 ± 4.2 kg/m2, respec-
tively. Both body weight and HbA1c were
reduced in 67.7% of patients, and HbA1c was
lowered in 75.1%. Younger age, male sex,
shorter diabetes duration, higher baseline
HbA1c and estimated glomerular filtration rate
(eGFR), and having dapagliflozin as add-on
therapy were associated with stronger HbA1c
reductions after dapagliflozin use (all P\0.05).
Moreover, subgroup analysis of eGFR of subjects
with renal hyperfiltration (eGFR C 120 ml/min/
1.73 m2) showed the largest reduction in glu-
cose level (% change, - 9.5; 95% CI - 6.8 to
- 12.3 for HbA1c; P\0.001). Multivariable
logistic regression analysis showed that recent
T2D diagnosis and higher HbA1c at baseline in
patients who received an add-on regimen of
dapagliflozin were statistically significantly
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associated with a dapagliflozin response (all
P\ 0.05).
Conclusions: Dapagliflozin provides benefits
for glycemic control and body weight. Patients
in a relatively early stage of the course of dia-
betes with renal hyperfiltration might be more
suitable for and gain maximal benefit from
dapagliflozin treatment.
Trial Registration: ClinicalTrials.gov identifier,
NCT02252224.
Funding: AstraZeneca.
Keywords: Clinical trials; Nephropathy;
Obesity; Pathophysiology; SGLT2 inhibitors
INTRODUCTION
Sodium glucose co-transport 2 (SGLT2) is a
member of a family of ATP-dependent proteins
located in the S1 segment of the proximal renal
tubules and manages up to 90% of the filtered
glucose reuptake by the concentration gradient
[1]. Inhibitors of SGLT2 comprise a novel class
of anti-diabetic agents that has been gaining
attention because of their unique mode of
action and effectiveness in lowering blood glu-
cose and reducing body weight independently
of insulin [2, 3]. In addition, recent studies
demonstrate that SGLT2 inhibitors have bene-
ficial effects on cardiovascular disease-related
mortality, blood pressure [4], hepatic steatosis
[5], and visceral fat mass [6].
Dapagliflozin is an SGLT2 inhibitor with
anti-hyperglycemic activity. Dapagliflozin
monotherapy reduces an average of 0.9% gly-
cated hemoglobin (HbA1c) and decreases body
weight by up to 3 kg in randomized controlled
trials (RCT) [7]. In combination with other anti-
diabetic medications, dapagliflozin provides
sustained glycemic control and body weight
reduction [2, 8]. Compared with metformin,
dapagliflozin therapy is superior in lowering
blood glucose [9]. With lower hypoglycemia risk
and high tolerability, dapagliflozin appears to
fulfill some unmet needs in diabetes manage-
ment [2].
Despite previous clinical studies demon-
strating the favorable effectiveness of dapagli-
flozin, there are limited reports on the
effectiveness of SGLT2 inhibitors in actual
clinical practice settings, especially in Korea.
Furthermore, the characteristics of patients who
respond to SGLT2 inhibitors have not been fully
determined. Thus, the aim of this study was to
investigate the characteristics of dapagliflozin
responders and evaluate the association
between the glucose-lowering effectiveness of
dapagliflozin and other clinical parameters in
an actual clinical setting.
METHODS
Design and Population
This investigation was a non-comparative,
prospective, non-interventional, regulatory
post-marketing surveillance (PMS) study (Clini-
calTrials.gov, no. NCT02252224) designed to
evaluate the safety and effectiveness of dapa-
gliflozin (Forxiga, 10 mg) in patients with type
2 diabetes mellitus (T2D). A total of 3371 T2D
patients from 123 medical facilities across Korea
who were being treated with dapagliflozin were
recruited from September 2014 to November
2016. Patients were recruited to be followed for
either 12 weeks (maximum 16 weeks) or
24 weeks (maximum 30 weeks). Patients fol-
lowed for 12 weeks accounted for the greater
part of the study population, as only 10% of the
total recruited patients at 12 weeks were
mandatorily required to have long-term follow-
up by the regulatory authority in Korea. For the
initial study design, all patients who had taken
at least one pill were included (n = 3371).
However, a total of 1364 patients were excluded
from analysis, as shown in Fig. 1. Only 2007
patients showed competent adherence to
dapagliflozin therapy and were included in the
effectiveness analysis at 12 weeks.
This study was conducted in compliance
with the ethical principles of the ‘‘Basic Stan-
dards for the Re-examination of New Medici-
nes’’ published by the Ministry of Food and
Drug Safety in Korea. Approval from the Insti-
tutional Review Board was obtained according
to the rules of each institution as required for a
PMS. All procedures followed were in accor-
dance with the ethical standards of the
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responsible committee on human experimen-
tation (institutional and national) and with the
Helsinki Declaration of 1964, as revised in 2013.
Informed consent was obtained from all
patients for being included in the study.
The patient population for this study con-
sisted of Korean patients who were at least
18 years of age, had been diagnosed with T2D,
and could start dapagliflozin therapy according
to a reasonable indication for treatment in an
ambulatory care setting. Patients were treated
by accredited physicians according to routine
practices at Korean healthcare centers
throughout the study. After receiving written
informed consent from the potential partici-
pants, each survey physician enrolled the
patients who were receiving dapagliflozin for
the first time and who had received at least one
dose. Each study participant was followed until
the observational periods were completed.
Exclusion criteria included patients who
were treated with dapagliflozin outside of clin-
ical relevance in Korea or who were con-
traindicated for the use of dapagliflozin.
Contraindications included (1) patients who
had a history of hypersensitivity to the active
substance or to any of the excipients, (2) type 1
diabetes mellitus or diabetic ketoacidosis
patients, (3) patients with hereditary problems
of galactose intolerance, lactase deficiency, or
glucose-galactose malabsorption, and (4)
patients with severe renal impairment (esti-
mated glomerular filtration rate [eGFR]\30 ml/
min/1.73 m2, calculated using the Chronic
Kidney Disease Epidemiology Collaboration
equation [10]), with end-stage renal disease, or
on dialysis. Other anti-diabetic medications
used by patients were maintained, titrated, or
switched in accordance with the physician’s
decision during the periods of dapagliflozin
treatment. Lifestyle modification therapy and
education for both diet and exercise were also
provided in parallel with medications.
Effectiveness Assessment
The comparable variables for the effectiveness of
dapagliflozin after 12 and 24 weeks of treatment
were changes in HbA1c, fasting plasma glucose
(FPG), postprandial glucose (PPG), body mass
index (BMI), and blood pressure. For PPG,
patients underwent a conventional 2-h oral glu-
cose tolerance test at baseline, 12 and 24 weeks
(in case of long-term surveillance). Analysis of the
effectiveness of dapagliflozin was conducted
Fig. 1 Study ﬂow diagram demonstrating analysis population. Post-marketing surveillance study designed to evaluate the
safety and effectiveness of dapagliﬂozin
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using stratified categorization with the respon-
siveness for the dapagliflozin treatment. Based on
a previous report [11], we arbitrarily defined the
responders as those exhibiting a C 10% reduction
in HbA1c values after 12 weeks of dapagliflozin
treatment. The relative change (D) was calculated
as [(baseline value) - (post-dapagliflozin treat-
ment value (C 12 weeks))]/(baseline value) 9 100
(%). The absolute D was calculated as [(baseline
value) - (post-dapagliflozin treatment value
(C 12 weeks))].
Safety Assessment
Patients participating in the study were exclu-
ded or withdrawn from the continuation of
treatment or the study for the following rea-
sons: loss of follow-up information, adverse
events, patient’s decision, or physician’s deci-
sion. If a patient discontinued the treatment
during the study, the patient was contacted to
collect all information regarding adverse events
and the reasons why they wanted to stop the
treatment. Patients who discontinued the study
were included in the safety population if they
had taken at least one dose of dapagliflozin.
Adverse events and serious adverse events
recorded in the electronic case report forms
were recoded and reanalyzed according to the
current routine classification [12].
Statistical Analysis
Data are presented as the mean ± standard devi-
ation for continuous variables and as number or
percentage for categorical variables. The simple
changes of blood pressure, glycemic and lipid
parameters after dapagliflozin treatment were
compared using a paired t test. For effectiveness
analysis, missing values were imputed using the
last observation carried forward method. A mixed
effect model repeated measure test among three
visits (baseline, C 12 and B 24 weeks, and
C 24 weeks) was performed only if each variable
was measured at[24 weeks. The receiver-oper-
ating characteristic (ROC) curve was also used for
calculating the cutoff value for the relative
change expectation of HbA1c levels[10% from
the baseline. Three groups were compared by one-
way analysis of variance (ANOVA) and Bonferroni
tests in terms of changes from the baselines for
detailed analysis according to eGFR. Scatter
graphs were rendered and correlation coefficients
calculated to confirm the correlation between
changes of HbA1c and body weight or between
relative HbA1c changes and baseline HbA1c. The
relative factors for dapagliflozin response were
obtained using univariate and multiple logistic
regressions. Risk is reported in the form of odds
ratios (ORs) and 95% confidence intervals (CIs).
All statistical analyses were performed using SAS
(version 9.4, SAS Institute, Cary, NC, USA) for the
calculations and NCSS (version 11, NCSS Co.,
Kaysville, UT, USA) for the graphics. P values
\0.05 were considered statistically significant.
RESULTS
Baseline Characteristics by Study
Population
A total of 2007 individuals with T2D were ana-
lyzed (Fig. 1). Patient baseline characteristics are
shown in Table 1. The mean age of the study
population was 52.8 years, and 51.1% were
female. The mean BMI was 28.1 kg/m2 and
mean waist circumference was 92.2 cm.
According to the definition of obesity in the
Asian Pacific Region Guideline (BMI C 25 kg/
m2) [13], 76.2% of the patients in this study
were obese. Although the duration of T2D was
relatively short (median 26.0 months), 22.3% of
the patients reported having T2D-related com-
plications. Dapagliflozin treatment was offered
as switch medication in 46.6% participants and
as add-on therapy in 53.3%. Over 90% of the
study population was prescribed metformin at
baseline. The baseline mean FPG, PPG, and
HbA1c were 166.2 mg/dl, 233.1 mg/dl, and
8.1%, respectively.
Effectiveness of Dapagliflozin on Glucose,
Body Weight, and Blood Pressure
After 12 weeks of treatment with dapagliflozin,
HbA1c, FPG, and PPG were statistically signifi-
cantly (P\0.001) lowered (from 8.1 ± 1.3% to
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7.5 ± 1.2%, absolute D - 0.6 ± 1.2% for
HbA1c; from 166.2 ± 48.8 to 139.6 ± 38.9 mg/
dl, absolute D - 26.6 ± 49.8 for FPG; from
233.1 ± 80.4 to 189.9 ± 66.4 mg/dl, absolute D
- 43.1 ± 84.9 mg/dl for PPG; Table 2). Body
weight and BMI were also significantly
(P\0.001) decreased after dapagliflozin treat-
ment (from 75.8 ± 15.0 to 73.9 ± 14.4 kg,
absolute D - 2.3 ± 2.6 kg for body weight; from
28.1 ± 4.4 to 27.6 ± 4.2 kg/m2, absolute D
- 0.9 ± 1.0 kg/m2 for BMI). More decreases in
glycemic and anthropometric parameters were
observed after 24 weeks of treatment with
dapagliflozin. Although blood pressure was in
the recommended cutoff range for T2D at
baseline, gradual significant declines
(P\0.001) in both systolic and diastolic blood
pressure were observed during dapagliflozin
treatment (128.1 ± 14.2 to 123.2 ± 13.7 mmHg
for systolic blood pressure; 77.8 ± 10.3 to
75.3 ± 10.3 mmHg for diastolic blood pressure).
Clinical Determinants Associated
with Dapagliflozin Response
Since dapagliflozin treatment was effective in
lowering body weight and glucose levels, we
explored the associations among relative chan-
ges in HbA1c, baseline HbA1c, and body weight.
The results shown in Fig. 2a indicate a strong
Table 1 Baseline characteristics of study population
Baseline parameter Value
Age (years); mean (SD) 52.8 (11.1)
Age C 50 years, N (%) 1296 (64.6)
Sex, N (%)
Male 982 (48.9)
Female 1025 (51.1)
Diabetes duration, months (IQR) 26.0 (3.9–65.6)
C 24 months, N (%) 472 (23.5)
Body weight, kg (SD) 75.8 (15.0)
BMI, kg/m2 (SD) 28.1 (4.4)
Obesity (C 25 kg/m2), N (%) 1092 (76.2)
Waist circumference, cm (SD) 92.2 (10.2)
SBP, mmHg (SD) 128.1 (14.2)
DBP, mmHg (SD) 77.8 (10.3)
FPG, mg/dl (SD) 166.2 (48.8)
PPG, mg/dl (SD) 233.1 (80.4)
HbA1c, % (SD) 8.1 (1.3)
Serum creatinine (mg/dl) 0.8 (0.2)
eGFR, ml/min/1.73 m2 (SD) 95.4 ± 15.6
Diabetes-related complications, N (%)
No 1559 (77.7)
Yes 448 (22.3)
Manner of dapagliﬂozin use, N (%)
Add-on 1069 (53.3)
Switch 936 (46.6)
Unknown 2 (0.1)
Anti-diabetic medication, N (%)
Monotherapy 75 (3.7)
Dual therapy 551 (27.4)
Triple therapy or more 1004 (50.0)
Add on to insulin 1025 (18.8)
Concomitant anti-diabetic medication,
N (%)
Metformin 1813 (90.3)
Table 1 continued
Baseline parameter Value
Sulfonylureas 752 (37.5)
Thiazolidinediones 215 (10.7)
DPP-4 inhibitor 820 (40.8)
Injection 425 (21.2)
Data for continuous variables are expressed as mean ± s-
tandard deviation (SD) and for categorical variables as
number (percent)
IQR interquartile range, BMI body mass index, SBP sys-
tolic blood pressure, DBP diastolic blood pressure, FPG
fasting plasma glucose, PPG postprandial glucose, HbA1c
glycated hemoglobin
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relationship between the baseline HbA1c value
and dapagliflozin-induced response in HbA1c
change (R2 = 0.27, P\ 0.001). The relative
HbA1c change was proportional to the baseline
HbA1c (Fig. 2b). However, the correlation
between baseline BMI and HbA1c change was
not statistically significant (R2 = 0.001,
P = 0.295, Fig. 2c). Of the 1180 patients with
both HbA1c and body weight information at
baseline and follow-up, 886 (75.1%) experi-
enced HbA1c reduction and 799 (67.7%)
achieved both HbA1c lowering and body weight
loss. More than a third of the patients in the
12-week dapagliflozin treatment group (761/
2007; 37.9%) experienced C 10% reduction in
HbA1c and were categorized as responders. The
optimal cutoff for baseline HbA1c in dapagli-
flozin response was 8.0% (Figure S1).
Clinical parameters associated with the
dapagliflozin response were determined using
logistic regression analysis. As shown in
Table 3, younger age, male sex, short duration
of T2D, higher glycemic parameters (HbA1c,
FPG, and PPG), lower BMI, and lower serum
creatinine with higher eGFR were linked with
a dapagliflozin response. The responses to
dapagliflozin were better when the SGLT2
inhibitor was used as an add-on therapy than
when it was used as monotherapy. Baseline
systolic blood pressure did not show any
association.
Renal Hyperfiltration, Adjusted
Determinants, and Dapagliflozin Response
Because lower serum creatinine with higher
eGFR was linked with a dapagliflozin response,
we stratified the data by eGFR and analyzed
changes during the study period (Table 4).
Individuals with higher baseline eGFR showed
statistically significant (P\0.001) responses in
glucose reduction and body weight loss (D
HbA1c 4.1%, 95% CI 3.1–5.2 for eGFR\90 ml/
min/1.73 m2; D HbA1c 7.6%, 95% CI 6.9–8.4 for
eGFR C 90 and\120 ml/min/1.73 m2; D HbA1c
9.5%, 95% CI 6.8–12.3 for eGFR C 120 ml/min/
1.73 m2). However, the changes in systolic and
diastolic blood pressure were not different
among eGFR groups (P = 0.457 for systolic
blood pressure, P = 0.548 for diastolic blood
pressure).
To assess the independent clinical determi-
nants related to dapagliflozin response, we per-
formed multiple logistic regression analyses
(Table 3). Individuals with an early T2D course
(adjusted OR 0.46 95% CI 0.30–0.69), higher
HbA1c at baseline (adjusted OR 3.12, 95% CI
2.48–3.92), and dapagliflozin use as an add-on
therapy (adjusted OR 2.71, 95% CI 1.72–4.27)
still showed statistical significance in dapagli-
flozin responses (all P\0.05). In contrast,
young age, male sex, hyperfiltration, and low
BMI (BMI \ 25 kg/m2) showed only an
Table 2 Changes of clinical parameters after dapagliﬂozin treatment for 12 and 24 weeks
Parameter 12 Weeks Change P value 24 Weeks Change P value
HbA1c, % (SD) 7.5 (1.2) - 0.6 (1.2) \ 0.001 7.2 (1.0) - 0.8 (1.2) \ 0.001
FPG, mg/dl (SD) 139.6 (38.9) - 26.6 (49.8) \ 0.001 133.9 (31.0) - 27.0 (48.8) \ 0.001
PPG, mg/dl (SD) 189.9 (66.4) - 43.1 (84.9) \ 0.001 172.1 (56.0) - 51.6 (92.6) \ 0.001
BMI, kg/m2(SD) 27.6 (4.2) - 0.9 (1.0) \ 0.001 27.6 (4.7) - 1.0 (1.3) \ 0.001
Weight, kg (SD) 73.9 (14.4) - 2.3 (2.6) \ 0.001 74.7 (16.0) - 2.7 (3.6) \ 0.001
SBP, mmHg (SD) 125.8 (13.2) - 3.1 (14.5) \ 0.001 123.2 (13.7) - 2.3 (13.9) \ 0.001
DBP, mmHg (SD) 76.7 (9.8) - 1.6 (10.2) \ 0.001 75.3 (10.3) - 1.1 (10.6) \ 0.001
Data are presented as mean ± standard deviations
HbA1c glycated hemoglobin, FPG fasting plasma glucose, PPG postprandial glucose, BMI body mass index, SBP systolic
blood pressure, DBP diastolic blood pressure
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increased trend in response to dapagliflozin
treatment that was not statistically significant.
Safety
During the dapagliflozin treatment period,
26.3% (886 out of 3371) reported adverse
events, and 57 (1.6%) serious adverse events
occurred (Table S1). Among the patients with
serious adverse events, 52 were reported as
completely recovered, 2 were in recovery, and 3
recovered with sequalae (traffic accident, right
hand fracture, spontaneous brain hemorrhage).
In addition, 127 (3.8%) patients reported renal
and urinary disorders (polyuria, nocturia, and
pollakiuria without progression to chronic kid-
ney disease), and 45 (1.3%) had genital infec-
tions, including 7 cases of urinary tract
infection, cystitis, and vaginitis. Vascular-re-
lated side effects included one case of ortho-
static hypotension and one case of
hypotension. There was no neoplasm develop-
ment or diagnosis during the study period.
DISCUSSION
Three significant findings emerged from this
study to discern the characteristics of
Fig. 2 Correlation among baseline glycated hemoglobin,
body mass index, and change in glycated hemoglobin after
12-week treatment with dapagliﬂozin. a Correlation
between baseline glycated hemoglobin (HbA1c) and
relative DHbA1c after 12-week treatment with
dapagliﬂozin. b Distribution of patients for the relation
between relative DHbA1c and baseline HbA1c. c Correla-
tion between baseline body mass index (BMI) and relative
DHbA1c after 12-week treatment with dapagliﬂozin
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dapagliflozin responders and associations
between the glucose-lowering effectiveness of
dapagliflozin and other clinical parameters in
an actual clinical setting. First, reductions in
HbA1c and BMI were observed among dapagli-
flozin-treated patients in a real-world setting.
Second, T2D patients with early diabetes course,
higher baseline HbA1c, and dapagliflozin treat-
ment as an add-on therapy were more likely to
have significant clinical responses to dapagli-
flozin. Third, lower serum creatinine and higher
eGFR were associated with a greater response to
dapagliflozin treatment.
Considering the glucose-lowering effective-
ness of dapagliflozin, 46.6% of the participants
were switched to dapagliflozin from another
medication and 53.3% participants had dapa-
gliflozin added on to their treatment at base-
line. Overall, 886 of 1180 (75.1%) enrolled
patients experienced HbA1c reductions. The
overall change of HbA1c over 24 weeks in the
actual clinical practice world was - 0.8%,
which is similar to the average 0.9% HbA1c
reduction of dapagliflozin monotherapy in a
previous RCT study [7]. This result indicates
that it could be clinically relevant for a
Table 3 Logistic regression analysis to determine variables associated with dapagliﬂozin responders (relative HbA1c
reduction C 10%) in 12 weeks
Variable Odds ratio 95% CI P value
Univariate
Age, years 0.99 0.98–0.99 0.003
Sex, male 1.26 1.06–1.51 0.011
Diabetes duration (C 24 months) 0.41 0.32–0.54 \ 0.001
Baseline BMI, kg/m2 0.97 0.95–0.99 0.013
Baseline SBP, mmHg 1.01 1.00–1.01 0.140
Baseline HbA1c, % 2.31 2.11–2.54 \ 0.001
Baseline FPG, mg/dl 1.01 1.01–1.02 \ 0.001
Baseline PPG, mg/dl 1.01 1.01–1.01 \ 0.001
Baseline creatinine, mg/dl 0.56 0.33–0.95 0.031
Baseline eGFR 1.01 1.01–1.02 \ 0.001
Anti-diabetic medication, add-on 2.49 2.07–3.01 \ 0.001
Multivariate
Age (C 50 years) 0.71 0.47–1.09 0.116
Sex, male 1.19 0.80–1.78 0.385
Diabetes duration (C 24 months) 0.46 0.30–0.69 0.001
Baseline BMI (C 25 kg/m2) 0.72 0.45–1.16 0.175
Baseline HbA1c, % 3.12 2.48–3.92 \ 0.001
Baseline eGFR, (C 90 ml/min/m2) 0.98 0.63–1.53 0.923
Anti-diabetic medication, add-on 2.71 1.72–4.27 \ 0.001
BMI body mass index, SBP systolic blood pressure, HbA1c glycated hemoglobin, FPG fasting plasma glucose, PPG post-
prandial glucose, eGFR estimated glomerular ﬁltration rate
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physician to prescribe an SGLT2 inhibitor for
T2D patients with some modifying factors that
would elicit the maximal effect of the SGLT2
inhibitor.
Characteristics of SGLT2 inhibitor respon-
ders in this study include higher baseline HbA1c
and preserved eGFR reflected by young age and
a shorter duration of diabetes. These character-
istics have been noted in previous studies. A
retrospective report showed that only higher
baseline HbA1c and preserved eGFR ([90 ml/
min/1.73 m2) had positive correlations with
glucose-lowering effectiveness [14]. Moreover,
in a pooled analysis report, the HbA1c-lowering
effect was decreased as eGFR declined [15].
A Japanese pilot study demonstrated that the
renal threshold of the glucose slope was signif-
icantly steeper in young (B 40 years) compared
with older adults ([40 years) suggesting that
the large response of urinary glucose excretion
in the young accounts for the better response of
SGLT2 inhibitors in young patients [16].
Similar to previous studies [14, 15, 17], a
significant association between body weight
change and glucose reduction was not observed
in our study. Because SGLT2 inhibitors impede
glucose reabsorption from the proximal renal
tubules, dapagliflozin induces a complimentary
increase in urinary glucose excretion [17]. There
are different results among numerous studies,
but whether the extent of urine glucose excre-
tion would drive the blood glucose decrease in a
dependent manner has not been fully investi-
gated. In a Japanese clinical trial, the young age
group (B 40 years) showed a better effectiveness
in glycemic control with a larger increase in
urine glucose excretion [16]. However, another
study reported that a larger urinary glucose
excretion did not reflect a better HbA1c reduc-
tion [18]. As expected, these results suggest that
the insulin-independent mechanism for the
glucose-lowering effect of an SGLT2 inhibitor is
not simple.
Higher eGFR was associated with dapagli-
flozin responders in this study. Interestingly,
there are reports that glomerular hyperfiltration
might predict the development of diabetes and
also be associated with obesity, hypertension,
and even sarcopenia [19–22]. In a healthy and
non-diabetic cohort, renal hyperfiltration was
correlated with postprandial glucose metabo-
lism and insulin sensitivity, whereas eGFR was
not related to BMI and blood pressure [23].
Furthermore, lower insulin sensitivity was
exhibited in a renal hyperfiltration group com-
pared with controls [22]. Based on these previ-
ous studies regarding the correlation of renal
hyperfiltration with insulin resistance and the
association of increased eGFR with the glucose-
lowering effects of dapagliflozin, we postulate
that the SGLT2 inhibitors could reduce
glomerular hyperfiltration and HbA1c in an
insulin-independent manner for T2D patients
with early diabetes and renal hyperfiltration. In
addition, improved glycemic status due to
SGLT2 inhibitor therapy might attenuate insu-
lin resistance or enhance inulin sensitivity
rather than modify insulin secretion. Indeed, in
the context of glucometabolic homeostasis, a
hyperinsulinemic euglycemic clamp study
demonstrated that SGLT2 inhibitor therapy
reduced insulin secretion and improved insulin
sensitivity of glucose uptake [24].
This study has some limitations. First, due to
the lack of information attributable to the nat-
ure of a PMS, we cannot assert a direct associa-
tion between renal hyperfiltration and changes
in those parameters after dapagliflozin treat-
ment. Second, we did not account for the
potential effect of other medications on renal
hyperfiltration, including the renin-an-
giotensin-aldosterone system. Third, we did not
measure the uric acid level in the current study.
Several studies have consistently reported that
SGLT2 inhibitor treatment decreases serum uric
acid by altering uric acid transport activity
[25–28]. It has been hypothesized that the car-
dio-protective effects of SGLT2 inhibitors arise
from uric acid-lowering effects [29]. In addition,
the uric acid-lowering effects are related to the
HbA1c reduction [27]. Fourth, even though
missing data were imputed using the last
observation carried forward method, only 1180
out of 2007 patients had all values for HbA1c
and body weight at both baseline and 12-week
follow-up, which was a limitation for data
analysis. Fourth, even though missing data were
imputed using the last observation carried for-
ward method, only 1180 out of 2007 patients
had all values for HbA1c and body weight at
1698 Diabetes Ther (2018) 9:1689–1701
both baseline and 12-week follow up, which was
a limitation for data analysis. Finally, as the
original purpose of the current study was post-
marketing surveillance, we only assessed the
effect of dapagliflozin up to 24 weeks. Further
studies are warranted for the long-term effects
of dapagliflozin. Despite these limitations, our
study has the advantages of utilizing data from
a large, population-based study and of explor-
ing the characteristics of Korean dapagliflozin
responders in a real-world setting.
CONCLUSIONS
This nationwide survey of a Korean population
demonstrated that a better response to dapa-
gliflozin therapy is expected in T2D patients
who are in a relatively early diabetes course with
uncontrolled hyperglycemia. In addition, renal
hyperfiltration might be associated with higher
dapagliflozin response. Further prospective,
well-designed, longitudinal studies with suffi-
cient laboratory resources are warranted to
establish the clinical factors that indicate the
use of an SGLT2 inhibitor and to identify opti-
mal combinations of an SGLT2 inhibitor with
other anti-diabetic medications.
ACKNOWLEDGEMENTS
Funding. Sponsorship for this study and
article processing charges were funded by Astra
Zeneca.
Authorship. All named authors meet the
International Committee of Medical Journal
Editors (ICMJE) criteria for authorship for this
article, take responsibility for the integrity of
the work as a whole, and have given their
approval for this version to be published.
Prior Presentation. The data were partially
presented at the 17th Congress of the Interna-
tional Diabetes Federation 5–8 December 2017
(abstract).
Disclosures. Eugene Han, Jae Hyeon Kim,
Woo Je Lee, and Byung-Wan Lee have nothing
to disclose. Ari Kim is an employee of AstraZe-
neca. Seung Jae Lee is a former employee of
AstraZeneca. Je-Yon Kim is a former employee
of AstraZeneca.
Compliance with Ethics Guidelines. This
study was conducted in compliance with the
ethical principles of the ‘‘Basic Standards for the
Re-examination of New Medicines’’ published
by the Ministry of Food and Drug Safety in
Korea. Approval from the Institutional Review
Board was obtained according to the rules of
each institution as required for a PMS. All pro-
cedures followed were in accordance with the
ethical standards of the responsible committee
on human experimentation (institutional and
national) and with the Helsinki Declaration of
1964, as revised in 2013. Informed consent was
obtained from all patients for being included in
the study.
Data Availability. The data sets during and/
or analyzed during the current study are avail-
able from the corresponding author on reason-
able request.
Open Access. This article is distributed
under the terms of the Creative Commons
Attribution-NonCommercial 4.0 International
License (http://creativecommons.org/licenses/
by-nc/4.0/), which permits any non-
commercial use, distribution, and reproduction
in any medium, provided you give appropriate
credit to the original author(s) and the source,
provide a link to the Creative Commons license,
and indicate if changes were made.
REFERENCES
1. Abdul-Ghani MA, Norton L, Defronzo RA. Role of
sodium-glucose cotransporter 2 (SGLT 2) inhibitors
in the treatment of type 2 diabetes. Endocr Rev.
2011;32(4):515–31.
2. Jung CH, Jang JE, Park JY. A novel therapeutic agent
for type 2 diabetes mellitus: SGLT2 inhibitor. Dia-
betes Metab J. 2014;38(4):261–73.
Diabetes Ther (2018) 9:1689–1701 1699
3. Min KW, Ku BJ, Lee JH, Kim MS, Ahn KJ, Lee MK,
et al. Addition of Ipragliflozin to metformin treat-
ment in Korean patients with type 2 diabetes mel-
litus: subgroup analysis of a phase 3 trial. Diabetes
Metab J. 2017;41(2):135–45.
4. Zinman B, Wanner C, Lachin JM, Fitchett D,
Bluhmki E, Hantel S, et al. Empagliflozin, cardio-
vascular outcomes, and mortality in type 2 dia-
betes. N Engl J Med. 2015;373(22):2117–28.
5. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF.
Effect of dapagliflozin in patients with type 2 dia-
betes who have inadequate glycaemic control with
metformin: a randomised, double-blind, placebo-
controlled trial. Lancet. 2010;375(9733): 2223–33.
6. Bolinder J, Ljunggren O, Kullberg J, Johansson L,
Wilding J, Langkilde AM, et al. Effects of dapagli-
flozin on body weight, total fat mass, and regional
adipose tissue distribution in patients with type 2
diabetes mellitus with inadequate glycemic control
on metformin. J Clin Endocrinol Metab.
2012;97(3):1020–31.
7. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF.
Dapagliflozin monotherapy in type 2 diabetic
patients with inadequate glycemic control by diet
and exercise: a randomized, double-blind, placebo-
controlled, phase 3 trial. Diabetes Care.
2010;33(10):2217–24.
8. Rosenstock J, Vico M, Wei L, Salsali A, List JF. Effects
of dapagliflozin, an SGLT2 inhibitor, on HbA(1c),
body weight, and hypoglycemia risk in patients
with type 2 diabetes inadequately controlled on
pioglitazone monotherapy. Diabetes Care.
2012;35(7):1473–8.
9. Henry RR, Murray AV, Marmolejo MH, Hennicken
D, Ptaszynska A, List JF. Dapagliflozin, metformin
XR, or both: initial pharmacotherapy for type 2
diabetes, a randomised controlled trial. Int J Clin
Pract. 2012;66(5):446–56.
10. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro
AF 3rd, Feldman HI, et al. A new equation to esti-
mate glomerular filtration rate. Ann Intern Med.
2009;150(9):604–12.
11. Han E, Park HS, Kwon O, Choe EY, Wang HJ, Lee
YH, et al. A genetic variant in GLP1R is associated
with response to DPP-4 inhibitors in patients with
type 2 diabetes. Medicine (Baltim). 2016;95(44):
e5155.
12. International Council for Harmonisation of tech-
nical requirements for registration of pharmaceuti-
cals for human use. Medical Dictionary for
Regulatory Activities Version 181, Geneva. 2015.
13. Kim CS, Ko SH, Kwon HS, Kim NH, Kim JH, Lim S,
et al. Prevalence, awareness, and management of
obesity in Korea: data from the Korea national
health and nutrition examination survey
(1998–2011). Diabetes Metab J. 2014;38(1):35–43.
14. Lee JY, Kim G, Kim SR, Lee YH, Lee BW, Cha BS,
et al. Clinical parameters affecting dapagliflozin
response in patients with type 2 diabetes. Diabetes
Metab. 2017;43(2):191–4.
15. Petrykiv S, Sjostrom CD, Greasley PJ, Xu J, Persson
F, Heerspink HJL. Differential effects of dapagli-
flozin on cardiovascular risk factors at varying
degrees of renal function. Clin J Am Soc Nephrol.
2017;12(5):751–9.
16. Nakamura Y, Nagai Y, Terashima Y, Nishine A, Ishii
S, Kato H, et al. Better response to the SGLT2 inhi-
bitor dapagliflozin in young adults with type 2
diabetes. Expert Opin Pharmacother. 2015;16(17):
2553–9.
17. Zhang L, Feng Y, List J, Kasichayanula S, Pfister M.
Dapagliflozin treatment in patients with different
stages of type 2 diabetes mellitus: effects on gly-
caemic control and body weight. Diabetes Obes
Metab. 2010;12(6):510–6.
18. Kim SR, Lee YH, Kang ES, Cha BS, Lee BW. The
relationship between Increases in morning spot
urinary glucose excretion and decreases in HbA1C
in patients with type 2 diabetes after taking an
SGLT2 inhibitor: a retrospective, longitudinal
study. Diabetes Ther. 2017;8(3):601–9.
19. Han E, Lee YH, Lee BW, Kang ES, Cha BS. Pre-sar-
copenia is associated with renal hyperfiltration
independent of obesity or insulin resistance:
Nationwide Surveys (KNHANES 2008–2011). Medi-
cine (Baltim). 2017;96(26):e7165.
20. Helal I, Fick-Brosnahan GM, Reed-Gitomer B,
Schrier RW. Glomerular hyperfiltration: definitions,
mechanisms and clinical implications. Nat Rev
Nephrol. 2012;8(5):293–300.
21. Sim EH, Lee HW, Choi HJ, Jeong DW, Son SM, Kang
YH. The association of serum cystatin C with gly-
cosylated hemoglobin in Korean adults. Diabetes
Metab J. 2016;40(1):62–9.
22. Tomaszewski M, Charchar FJ, Maric C, McClure J,
Crawford L, Grzeszczak W, et al. Glomerular
hyperfiltration: a new marker of metabolic risk.
Kidney Int. 2007;71(8):816–21.
23. Naderpoor N, Lyons JG, Mousa A, Ranasinha S,
Courten MP, Soldatos G, et al. Higher glomerular
filtration rate is related to insulin resistance but not
to obesity in a predominantly obese non-diabetic
cohort. Sci Rep. 2017;7:45522.
1700 Diabetes Ther (2018) 9:1689–1701
24. Ferrannini E, Muscelli E, Frascerra S, Baldi S, Mari A,
Heise T, et al. Metabolic response to sodium-glucose
cotransporter 2 inhibition in type 2 diabetic
patients. J Clin Invest. 2014;124(2):499–508.
25. Davies MJ, Trujillo A, Vijapurkar U, Damaraju CV,
Meininger G. Effect of canagliflozin on serum uric
acid in patients with type 2 diabetes mellitus. Dia-
betes Obes Metab. 2015;17(4):426–9.
26. Chino Y, Samukawa Y, Sakai S, Nakai Y, Yamaguchi
J, Nakanishi T, et al. SGLT2 inhibitor lowers serum
uric acid through alteration of uric acid transport
activity in renal tubule by increased glycosuria.
Biopharm Drug Dispos. 2014;35(7):391–404.
27. Ouchi M, Oba K, Kaku K, Suganami H, Yoshida A,
Fukunaka Y, et al. Uric acid lowering in relation to
HbA1c reductions with the SGLT2 inhibitor tofo-
gliflozin. Diabetes Obes Metab. 2018;20(4):1061–5.
28. Zhao Y, Xu L, Tian D, Xia P, Zheng H, Wang L, et al.
Effects of sodium-glucose co-transporter 2 (SGLT2)
inhibitors on serum uric acid level: a meta-analysis
of randomized controlled trials. Diabetes Obes
Metab. 2018;20(2):458–62.
29. Zoppini G, Targher G, Negri C, Stoico V, Perrone F,
Muggeo M, et al. Elevated serum uric acid concen-
trations independently predict cardiovascular mor-
tality in type 2 diabetic patients. Diabetes Care.
2009;32(9):1716–20.
Diabetes Ther (2018) 9:1689–1701 1701
